GlassScriptPhysician profile
Bareia N Chaudhry
NPI 1407219728
$1,133.64
in general payments reported to CMS, 2019-2025
25 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $407 · 2024: $616 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.64 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2023 | Ninlaro |
| Janssen Biotech, INC. | $101.02 | 2024 | Talvey, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $92.96 | 2023-2024 | Imfinzi |
| Lilly USA, LLC | $92.11 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Incyte Corporation | $77.42 | 2023-2024 | Monjuvi, Pemazyre, Zynyz |
| Ipsen Biopharmaceuticals, INC | $75.67 | 2023-2024 | Tazverik, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $72.19 | 2023-2024 | |
| Daiichi Sankyo INC. | $58.25 | 2024-2025 | Enhertu |
| Pfizer INC. | $50.89 | 2023-2024 | |
| Amgen INC. | $44.66 | 2023 | Kyprolis |
| Glaxosmithkline, LLC. | $44.31 | 2024-2025 | Blenrep, Jemperli |
| Menarini Silicon Biosystems, INC. | $29.81 | 2025 | |
| Genzyme Corporation | $28.82 | 2024 | |
| Sobi, INC | $27.97 | 2024 | |
| Beigene USA, INC. | $26.91 | 2024 | Brukinsa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.78 | 2023 | Trodelvy |
| Progenics Pharmaceuticals, INC. | $24.13 | 2024 | |
| Merck Sharp & Dohme LLC | $22.14 | 2024 | Keytruda |
| Emd Serono, INC. | $20.85 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.40 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Exelixis INC. | $14.71 | 2024 | Cabometyx |
| Acrotech Biopharma INC. | $14.44 | 2024 | Beleodaq |
| Abbvie INC. | $14.23 | 2025 | |
| Celgene Corporation | $13.98 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bareia Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.